Genetic Analysis Market by Product Type (Consumables, Instruments, Services), Technology (Microarray, Next Generation Sequencing, Polymerase Chain Reaction), Application, End User - Global Forecast 2025-2032
Description
The Genetic Analysis Market was valued at USD 10.94 billion in 2024 and is projected to grow to USD 11.73 billion in 2025, with a CAGR of 8.45%, reaching USD 20.94 billion by 2032.
A forward-looking introduction framing genetic analysis priorities, stakeholder expectations, regulatory dynamics, and near-term technological inflections
The genetic analysis landscape is at an inflection point, shaped by converging technological advances, evolving clinical demands, and a more complex regulatory and commercial environment. This introduction situates readers within that context by clarifying the core value propositions that genetic testing delivers across diagnostic pathways, research workflows, and therapeutic development. It outlines the central stakeholders-laboratories, clinicians, pharmaceutical developers, instrument and reagent suppliers, and payers-and highlights their sometimes-competing priorities around accuracy, turnaround time, cost, and regulatory compliance.
Moving from high-level context to practical relevance, the introduction emphasizes how technology maturation and shifting practice patterns are creating new use cases. Laboratories are balancing high-throughput sequencing with targeted assays, while healthcare systems are assessing integration pathways that align genomic data with electronic health records and clinical decision support. The introduction also frames the operational pressures that leaders face, including supply continuity, reagent lifecycle management, and workforce capability building, offering a clear starting point for the more granular insights that follow. Transitional commentary prepares the reader for deeper analysis of transformative shifts, tariff impacts, segmentation dynamics, regional considerations, competitive moves, and actionable recommendations.
Transformational shifts reshaping genetic analysis markets driven by converging technologies, reimbursement trends, supply chain realignment evolving priorities
The landscape of genetic analysis is undergoing transformative shifts that extend well beyond incremental improvements in assay sensitivity. At a technological level, the maturation of parallel sequencing platforms and the growing sophistication of bioinformatics are enabling more comprehensive and clinically actionable readouts. Simultaneously, point-of-care molecular modalities are expanding diagnostic reach, while high-throughput laboratory automation continues to redefine throughput economics and workforce allocations. These shifts are influencing laboratory design, capital allocation, and the integration of digital platforms for data curation and clinical reporting.
On the clinical and commercial fronts, the move from single-gene testing to multi-gene panels and broader genomic profiling is altering payer conversations and clinical pathways. Reimbursement dynamics and value-based care initiatives are prompting providers to demand clearer evidence of clinical utility, which in turn drives the need for more robust outcome studies and real-world evidence generation. Additionally, supply chain realignment-accelerated by geopolitical developments and trade policy-has prompted organizations to rethink sourcing strategies, inventory buffers, and contract structures. Taken together, these forces are reshaping investment priorities and partnership models, and they create both challenges and opportunities for innovators and incumbent players alike.
Assessment of United States tariff adjustments in 2025 and their cumulative influence on genetic analysis supply chains, procurement choices, innovation incentives
Tariff adjustments enacted in 2025 introduced new frictions into the global sourcing and procurement of genetic analysis inputs, compelling stakeholders to reassess supply chains, cost structures, and vendor relationships. The immediate practical impact has been most evident in categories where finished instruments and specialized reagents cross borders, prompting procurement teams to revisit total landed cost assumptions, lead times, and service agreements. In many cases, organizations have moved to diversify suppliers or to qualify regional distributors to mitigate exposure to single-source import channels.
Beyond procurement mechanics, tariffs have had strategic implications for product roadmaps and commercial positioning. Vendors dependent on cross-border manufacturing have accelerated local assembly or regional distribution models to preserve price competitiveness and service reliability. Meanwhile, laboratory and clinical customers have increased emphasis on instrument uptime, spare parts availability, and consumable compatibility to avoid operational disruptions. Importantly, the tariff environment has heightened interest in collaborative contracting, multisupplier frameworks, and longer-term supply agreements that include flexibility clauses for policy volatility. These shifts reinforce the need for procurement professionals and business leaders to align procurement strategy with clinical priorities, regulatory compliance, and continuity planning, and to adopt scenario-based approaches that maintain research and diagnostic continuity.
Segmentation-driven insight into how technology modalities, clinical applications, product types, and end-user dynamics shape adoption and investment trajectories
Examining segmentation reveals distinct drivers of adoption and investment across technology, application, product type, and end-user groups, each of which requires tailored strategies. Based on technology, the market is studied across Microarray, Next Generation Sequencing, Polymerase Chain Reaction, and Sanger Sequencing; these modalities present different cost structures, informatics needs, and validation pathways, with NGS offering breadth and PCR providing speed and targeted sensitivity. Based on application, the market is studied across Clinical Diagnostics, Genetic Disease, Infectious Disease, Oncology, and Reproductive Health; use cases within oncology and reproductive health often demand high analytical precision and rapid clinical interpretation, while infectious disease workflows prioritize scalability and speed.
Based on product type, the market is studied across Consumables, Instruments, Services, and Software, and each product class interacts with procurement and operational models differently: consumables drive recurring revenue and inventory concerns, instruments represent capital expenditure and depreciation considerations, services provide flexible capacity and expertise, and software underpins data analysis and regulatory compliance. Based on end user, the market is studied across Contract Research Organizations, Diagnostic Laboratories, Hospitals, Pharmaceutical Companies, and Research Institutes, each with unique purchasing criteria, throughput expectations, and regulatory responsibilities. Collectively, these segmentation lenses explain heterogeneous adoption curves, clinical integration rates, and vendor value propositions, and they inform how stakeholders should prioritize product development, go-to-market tactics, and partnerships.
Regional insights across the Americas, Europe Middle East & Africa and Asia Pacific that expose infrastructure priorities, regulatory nuance and workforce trends
Regional dynamics influence not only where innovation occurs but also how it is commercialized and regulated. The Americas continue to be a nexus for commercial-scale laboratory deployment, private investment, and payer-driven evidence generation, with mature reimbursement conversations guiding clinical adoption. In Europe, Middle East & Africa, regulatory harmonization efforts and variable national reimbursement landscapes create both complexity and opportunity for vendors that can navigate divergent pathways and offer adaptable service models. Asia-Pacific demonstrates deep regional variation, where some markets prioritize local manufacturing and domestic scaling while others focus on rapid adoption of cutting-edge sequencing and diagnostic platforms.
These geographic patterns affect infrastructure priorities, talent development, and partnership approaches. For example, investment in centralized sequencing hubs versus distributed testing networks will vary by region and will be shaped by healthcare delivery models, logistical constraints, and workforce availability. Regulatory nuance across these regions also influences validation timelines and data localization strategies, and organizations should align clinical evidence generation and commercialization plans with regional expectations. Transitioning from regional insight to execution means matching product, service, and commercial models to local procurement norms, clinical workflows, and talent pipelines to ensure sustainable adoption and scale.
Company-level insights into product portfolios, R&D focus, go-to-market models, partnership ecosystems, and the evolving balance of instruments versus services
Company-level dynamics center on differentiation through technology platforms, breadth of consumable ecosystems, and the ability to integrate software and services as part of a holistic offering. Leading vendors continue to invest in R&D to drive assay sensitivity, reduce hands-on time, and enhance informatics pipelines, while service providers expand offerings to include end-to-end solutions that lower barriers for clinical adoption. Strategic partnerships and alliances have become central to scaling capabilities quickly; companies are increasingly forming collaborations with instrument makers, reagent suppliers, and software developers to deliver validated, interoperable solutions.
At the same time, go-to-market models are evolving. Some firms emphasize capital-light approaches by expanding services and subscription-based consumable models, whereas others pursue traditional instrument sales complemented by service contracts. Mergers and acquisitions remain a tactical lever to acquire niche capabilities or to accelerate entry into adjacent applications. Competitive positioning now hinges on the ability to demonstrate clinical utility, ensure supply resilience, and provide a seamless data-to-decision workflow. For stakeholders, understanding where competitors prioritize R&D spend, which partnerships they cultivate, and how they structure commercial agreements is essential to anticipating market moves and identifying white-space opportunities.
Strategic recommendations for leaders to accelerate innovation, fortify supply chains, optimize procurement, and align commercial strategy with clinical priorities
Industry leaders should pursue a set of pragmatic, prioritized actions that convert insight into measurable outcomes. First, align product development with validated clinical pathways and payer evidence requirements to accelerate adoption and reimbursement negotiation. Second, redesign supply chain strategies to incorporate multi-sourcing, regional distribution, and contractual flexibility so that tariff or geopolitical shocks have reduced operational impact. Third, invest in software and analytics that streamline data interpretation and reporting, recognizing that informatics is increasingly a differentiator in delivering clinical value.
Leaders should also reconsider commercial models, exploring subscription and managed-service approaches that lower the barrier to entry for high-cost instrumentation while creating predictable revenue streams. Workforce development is another priority: invest in training programs, standardized protocols, and remote-support capabilities to maximize throughput and consistency. Finally, establish clear partnership frameworks to share risk and accelerate validation efforts, leveraging contract research organizations, academic collaborations, and clinical networks where appropriate. By sequencing these initiatives-beginning with evidence generation and supply resilience, then moving to commercialization and workforce enablement-organizations can improve agility while protecting clinical continuity.
Research methodology outlining primary and secondary techniques, stakeholder interviews, data triangulation, and validation steps that ensure analytical rigor
The research methodology combined primary engagement with domain experts, structured secondary analysis, and systematic validation steps to ensure analytical rigor and relevance. Primary research included interviews with laboratory directors, procurement leads, clinical investigators, and vendor executives to capture decision criteria, operational constraints, and technology adoption drivers. These interviews were complemented by site visits and virtual walkthroughs to observe workflows, instrumentation footprints, and inventory management practices in real-world settings.
Secondary research involved a review of peer-reviewed literature, regulatory guidance documents, patent filings, and public technical documentation to map technology capabilities and validation requirements. Data triangulation occurred through cross-referencing qualitative insights with product specifications, regulatory approvals, and published performance studies. Validation steps included internal expert review, scenario testing for supply chain and tariff impacts, and iterative revisions based on stakeholder feedback to refine assumptions and implications. This layered methodology underpins the report’s conclusions, ensuring that recommendations are both evidence-based and operationally grounded.
Synthesis of strategic implications, stakeholder responsibilities, technological levers, next steps to advance genetic analysis responsibly and sustainably
The synthesis integrates strategic implications, stakeholder responsibilities, and practical levers that can accelerate responsible advancement in genetic analysis. Decision-makers face a dual imperative: to rapidly integrate powerful technologies that improve diagnostic and research capabilities, while simultaneously ensuring quality, regulatory compliance, and equitable access. The strategic implications are clear-organizations that invest deliberately in evidence generation, data interoperability, and supply resilience will be better positioned to translate technical capability into clinical impact.
Stakeholder responsibilities include transparent validation of assays, proactive management of supply and workforce risks, and meaningful engagement with payers and clinicians to demonstrate clinical and economic value. Technological levers-such as automation, modular instrument design, and advanced analytics-can reduce operational friction, but they require careful implementation and verification. The next steps for leaders are practical: prioritize cross-functional initiatives that link clinical evidence to procurement strategy, build flexible supplier networks, and ensure that data governance practices support both innovation and patient privacy. In doing so, organizations will advance genetic analysis in a way that is scientifically robust, commercially viable, and ethically responsible.
Note: PDF & Excel + Online Access - 1 Year
A forward-looking introduction framing genetic analysis priorities, stakeholder expectations, regulatory dynamics, and near-term technological inflections
The genetic analysis landscape is at an inflection point, shaped by converging technological advances, evolving clinical demands, and a more complex regulatory and commercial environment. This introduction situates readers within that context by clarifying the core value propositions that genetic testing delivers across diagnostic pathways, research workflows, and therapeutic development. It outlines the central stakeholders-laboratories, clinicians, pharmaceutical developers, instrument and reagent suppliers, and payers-and highlights their sometimes-competing priorities around accuracy, turnaround time, cost, and regulatory compliance.
Moving from high-level context to practical relevance, the introduction emphasizes how technology maturation and shifting practice patterns are creating new use cases. Laboratories are balancing high-throughput sequencing with targeted assays, while healthcare systems are assessing integration pathways that align genomic data with electronic health records and clinical decision support. The introduction also frames the operational pressures that leaders face, including supply continuity, reagent lifecycle management, and workforce capability building, offering a clear starting point for the more granular insights that follow. Transitional commentary prepares the reader for deeper analysis of transformative shifts, tariff impacts, segmentation dynamics, regional considerations, competitive moves, and actionable recommendations.
Transformational shifts reshaping genetic analysis markets driven by converging technologies, reimbursement trends, supply chain realignment evolving priorities
The landscape of genetic analysis is undergoing transformative shifts that extend well beyond incremental improvements in assay sensitivity. At a technological level, the maturation of parallel sequencing platforms and the growing sophistication of bioinformatics are enabling more comprehensive and clinically actionable readouts. Simultaneously, point-of-care molecular modalities are expanding diagnostic reach, while high-throughput laboratory automation continues to redefine throughput economics and workforce allocations. These shifts are influencing laboratory design, capital allocation, and the integration of digital platforms for data curation and clinical reporting.
On the clinical and commercial fronts, the move from single-gene testing to multi-gene panels and broader genomic profiling is altering payer conversations and clinical pathways. Reimbursement dynamics and value-based care initiatives are prompting providers to demand clearer evidence of clinical utility, which in turn drives the need for more robust outcome studies and real-world evidence generation. Additionally, supply chain realignment-accelerated by geopolitical developments and trade policy-has prompted organizations to rethink sourcing strategies, inventory buffers, and contract structures. Taken together, these forces are reshaping investment priorities and partnership models, and they create both challenges and opportunities for innovators and incumbent players alike.
Assessment of United States tariff adjustments in 2025 and their cumulative influence on genetic analysis supply chains, procurement choices, innovation incentives
Tariff adjustments enacted in 2025 introduced new frictions into the global sourcing and procurement of genetic analysis inputs, compelling stakeholders to reassess supply chains, cost structures, and vendor relationships. The immediate practical impact has been most evident in categories where finished instruments and specialized reagents cross borders, prompting procurement teams to revisit total landed cost assumptions, lead times, and service agreements. In many cases, organizations have moved to diversify suppliers or to qualify regional distributors to mitigate exposure to single-source import channels.
Beyond procurement mechanics, tariffs have had strategic implications for product roadmaps and commercial positioning. Vendors dependent on cross-border manufacturing have accelerated local assembly or regional distribution models to preserve price competitiveness and service reliability. Meanwhile, laboratory and clinical customers have increased emphasis on instrument uptime, spare parts availability, and consumable compatibility to avoid operational disruptions. Importantly, the tariff environment has heightened interest in collaborative contracting, multisupplier frameworks, and longer-term supply agreements that include flexibility clauses for policy volatility. These shifts reinforce the need for procurement professionals and business leaders to align procurement strategy with clinical priorities, regulatory compliance, and continuity planning, and to adopt scenario-based approaches that maintain research and diagnostic continuity.
Segmentation-driven insight into how technology modalities, clinical applications, product types, and end-user dynamics shape adoption and investment trajectories
Examining segmentation reveals distinct drivers of adoption and investment across technology, application, product type, and end-user groups, each of which requires tailored strategies. Based on technology, the market is studied across Microarray, Next Generation Sequencing, Polymerase Chain Reaction, and Sanger Sequencing; these modalities present different cost structures, informatics needs, and validation pathways, with NGS offering breadth and PCR providing speed and targeted sensitivity. Based on application, the market is studied across Clinical Diagnostics, Genetic Disease, Infectious Disease, Oncology, and Reproductive Health; use cases within oncology and reproductive health often demand high analytical precision and rapid clinical interpretation, while infectious disease workflows prioritize scalability and speed.
Based on product type, the market is studied across Consumables, Instruments, Services, and Software, and each product class interacts with procurement and operational models differently: consumables drive recurring revenue and inventory concerns, instruments represent capital expenditure and depreciation considerations, services provide flexible capacity and expertise, and software underpins data analysis and regulatory compliance. Based on end user, the market is studied across Contract Research Organizations, Diagnostic Laboratories, Hospitals, Pharmaceutical Companies, and Research Institutes, each with unique purchasing criteria, throughput expectations, and regulatory responsibilities. Collectively, these segmentation lenses explain heterogeneous adoption curves, clinical integration rates, and vendor value propositions, and they inform how stakeholders should prioritize product development, go-to-market tactics, and partnerships.
Regional insights across the Americas, Europe Middle East & Africa and Asia Pacific that expose infrastructure priorities, regulatory nuance and workforce trends
Regional dynamics influence not only where innovation occurs but also how it is commercialized and regulated. The Americas continue to be a nexus for commercial-scale laboratory deployment, private investment, and payer-driven evidence generation, with mature reimbursement conversations guiding clinical adoption. In Europe, Middle East & Africa, regulatory harmonization efforts and variable national reimbursement landscapes create both complexity and opportunity for vendors that can navigate divergent pathways and offer adaptable service models. Asia-Pacific demonstrates deep regional variation, where some markets prioritize local manufacturing and domestic scaling while others focus on rapid adoption of cutting-edge sequencing and diagnostic platforms.
These geographic patterns affect infrastructure priorities, talent development, and partnership approaches. For example, investment in centralized sequencing hubs versus distributed testing networks will vary by region and will be shaped by healthcare delivery models, logistical constraints, and workforce availability. Regulatory nuance across these regions also influences validation timelines and data localization strategies, and organizations should align clinical evidence generation and commercialization plans with regional expectations. Transitioning from regional insight to execution means matching product, service, and commercial models to local procurement norms, clinical workflows, and talent pipelines to ensure sustainable adoption and scale.
Company-level insights into product portfolios, R&D focus, go-to-market models, partnership ecosystems, and the evolving balance of instruments versus services
Company-level dynamics center on differentiation through technology platforms, breadth of consumable ecosystems, and the ability to integrate software and services as part of a holistic offering. Leading vendors continue to invest in R&D to drive assay sensitivity, reduce hands-on time, and enhance informatics pipelines, while service providers expand offerings to include end-to-end solutions that lower barriers for clinical adoption. Strategic partnerships and alliances have become central to scaling capabilities quickly; companies are increasingly forming collaborations with instrument makers, reagent suppliers, and software developers to deliver validated, interoperable solutions.
At the same time, go-to-market models are evolving. Some firms emphasize capital-light approaches by expanding services and subscription-based consumable models, whereas others pursue traditional instrument sales complemented by service contracts. Mergers and acquisitions remain a tactical lever to acquire niche capabilities or to accelerate entry into adjacent applications. Competitive positioning now hinges on the ability to demonstrate clinical utility, ensure supply resilience, and provide a seamless data-to-decision workflow. For stakeholders, understanding where competitors prioritize R&D spend, which partnerships they cultivate, and how they structure commercial agreements is essential to anticipating market moves and identifying white-space opportunities.
Strategic recommendations for leaders to accelerate innovation, fortify supply chains, optimize procurement, and align commercial strategy with clinical priorities
Industry leaders should pursue a set of pragmatic, prioritized actions that convert insight into measurable outcomes. First, align product development with validated clinical pathways and payer evidence requirements to accelerate adoption and reimbursement negotiation. Second, redesign supply chain strategies to incorporate multi-sourcing, regional distribution, and contractual flexibility so that tariff or geopolitical shocks have reduced operational impact. Third, invest in software and analytics that streamline data interpretation and reporting, recognizing that informatics is increasingly a differentiator in delivering clinical value.
Leaders should also reconsider commercial models, exploring subscription and managed-service approaches that lower the barrier to entry for high-cost instrumentation while creating predictable revenue streams. Workforce development is another priority: invest in training programs, standardized protocols, and remote-support capabilities to maximize throughput and consistency. Finally, establish clear partnership frameworks to share risk and accelerate validation efforts, leveraging contract research organizations, academic collaborations, and clinical networks where appropriate. By sequencing these initiatives-beginning with evidence generation and supply resilience, then moving to commercialization and workforce enablement-organizations can improve agility while protecting clinical continuity.
Research methodology outlining primary and secondary techniques, stakeholder interviews, data triangulation, and validation steps that ensure analytical rigor
The research methodology combined primary engagement with domain experts, structured secondary analysis, and systematic validation steps to ensure analytical rigor and relevance. Primary research included interviews with laboratory directors, procurement leads, clinical investigators, and vendor executives to capture decision criteria, operational constraints, and technology adoption drivers. These interviews were complemented by site visits and virtual walkthroughs to observe workflows, instrumentation footprints, and inventory management practices in real-world settings.
Secondary research involved a review of peer-reviewed literature, regulatory guidance documents, patent filings, and public technical documentation to map technology capabilities and validation requirements. Data triangulation occurred through cross-referencing qualitative insights with product specifications, regulatory approvals, and published performance studies. Validation steps included internal expert review, scenario testing for supply chain and tariff impacts, and iterative revisions based on stakeholder feedback to refine assumptions and implications. This layered methodology underpins the report’s conclusions, ensuring that recommendations are both evidence-based and operationally grounded.
Synthesis of strategic implications, stakeholder responsibilities, technological levers, next steps to advance genetic analysis responsibly and sustainably
The synthesis integrates strategic implications, stakeholder responsibilities, and practical levers that can accelerate responsible advancement in genetic analysis. Decision-makers face a dual imperative: to rapidly integrate powerful technologies that improve diagnostic and research capabilities, while simultaneously ensuring quality, regulatory compliance, and equitable access. The strategic implications are clear-organizations that invest deliberately in evidence generation, data interoperability, and supply resilience will be better positioned to translate technical capability into clinical impact.
Stakeholder responsibilities include transparent validation of assays, proactive management of supply and workforce risks, and meaningful engagement with payers and clinicians to demonstrate clinical and economic value. Technological levers-such as automation, modular instrument design, and advanced analytics-can reduce operational friction, but they require careful implementation and verification. The next steps for leaders are practical: prioritize cross-functional initiatives that link clinical evidence to procurement strategy, build flexible supplier networks, and ensure that data governance practices support both innovation and patient privacy. In doing so, organizations will advance genetic analysis in a way that is scientifically robust, commercially viable, and ethically responsible.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increasing adoption of whole genome sequencing for personalized disease prevention strategies
- 5.2. Integration of artificial intelligence and machine learning in genomic variant interpretation pipelines
- 5.3. Rise of direct-to-consumer genetic testing services offering ancestry and health reports
- 5.4. Growth of long-read sequencing technologies enabling detection of structural genomic variants
- 5.5. Expansion of pharmacogenomics applications for tailored drug dosing and therapy selection
- 5.6. Emergence of portable nanopore sequencers for rapid on-site genetic analysis in remote settings
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Genetic Analysis Market, by Product Type
- 8.1. Consumables
- 8.2. Instruments
- 8.3. Services
- 8.4. Software
- 9. Genetic Analysis Market, by Technology
- 9.1. Microarray
- 9.2. Next Generation Sequencing
- 9.3. Polymerase Chain Reaction
- 9.4. Sanger Sequencing
- 10. Genetic Analysis Market, by Application
- 10.1. Clinical Diagnostics
- 10.2. Genetic Disease
- 10.3. Infectious Disease
- 10.4. Oncology
- 10.5. Reproductive Health
- 11. Genetic Analysis Market, by End User
- 11.1. Contract Research Organizations
- 11.2. Diagnostic Laboratories
- 11.3. Hospitals
- 11.4. Pharmaceutical Companies
- 11.5. Research Institutes
- 12. Genetic Analysis Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Genetic Analysis Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Genetic Analysis Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Agilent Technologies, Inc.
- 15.3.2. Beam Therapeutics Inc.
- 15.3.3. BGI Group
- 15.3.4. Bio-Rad Laboratories, Inc.
- 15.3.5. CRISPR Therapeutics AG
- 15.3.6. Danaher Corporation
- 15.3.7. Editas Medicine, Inc.
- 15.3.8. F. Hoffmann-La Roche Ltd.
- 15.3.9. GenScript Biotech Corporation
- 15.3.10. Illumina, Inc.
- 15.3.11. Intellia Therapeutics, Inc.
- 15.3.12. Merck KGaA
- 15.3.13. Myriad Genetics, Inc.
- 15.3.14. PerkinElmer, Inc.
- 15.3.15. QIAGEN N.V.
- 15.3.16. Sangamo Therapeutics, Inc.
- 15.3.17. Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
